Therapeutics for Immune System Disorders

25-Aug-2011 | News-Press Release

Bharatbook added a new report on "Therapeutics for Immune System Disorders" which gives the in-depth analysis and forecast on Therapeutics for Immune System Disorders


This study surveys the market for small–molecules and biologic therapies for diseases caused by disorders of the immune system: therapies covered are either already used or will be used as medicine within the next 5 years (through 2015).


In 2010, the global market for drugs for the treatment of immune disease was estimated to be approximately $72.2 billion. The market size is forecast to grow at a compound annual growth rate (CAGR) of 2.6% to reach $82.2 billion by 2015.

The market size of immunomodulators in 2010 is estimated to be $62.8 billion, accounting for 86.9% of the overall market. The market for immunomodulators is expected to grow by a compound annual growth rate (CAGR) of 3.4% to reach $74.1 billion by 2015, accounting for 90.2% of the market.

The demand for symptom–treating drugs is declining as advancements in immunology and life sciences help to target the underlying causes of the diseases. The market size of symptom treating diseases is expected to decline at a compound annual growth rate (CAGR) of –3.1% from $9.4 billion in 2010 to $8.1 billion in 2015.




This in–depth study examines recent commercial developments in immune disease treatments. There has been an explosion in knowledge concerning the immune system, and tremendous advancements in disease diagnosis and therapies with novel approaches – predominantly biologic–based treatments – replacing the traditional methods where emphasis was to treat the symptoms in order to improve the quality of life of the patient rather than treating the underlying cause of a disease. Over the past decade this new approach to immune disease has resulted in a wealth of new drugs and procedures that selectively target the causes of immune disease. This report forecasts that this trend will continue and the worldwide market for drugs that treat immune diseases will grow from an estimated $72.2 billion in 2010 to $82.2 billion by 2015. These diseases represent some of the largest market opportunities for pharmaceutical and biotechnology companies since they are common and chronic and historic treatments have been largely ineffective. The study examines the current market for the treatment of immune disease and then projects the effects of new technologies upon this market. It contains detailed analysis and provides market forecasts for the period of 2010 through 2015 and profiles the major companies involved in treating immune disease.

This report also analyzes various regulatory and market trends that will impact major immune disease segments during the forecast period. Challenges in the areas of technology and therapy are analyzed in detail and how these will be translated into important market trends and future business strategies are studied in depth and presented in the report. Finally, analysis of technology trends has been presented in the report, identifying how the most prevalent technologies in the market have changed over the past decade with the advent of biologics and future growth trends.( )


This report offers a broad, yet detailed, overview of immune disease and the drugs that treat immune disease. Pharmaceutical and biotechnology companies working in the field will find the report useful in that it provides an unbiased assessment of the market potential of this field. In addition, the report provides an explanation of both the technology and the market effects of various new developments that the field is facing such as new biologic targets that play key roles in different immune diseases; drugs with novel methods of delivery offering a leap in convenience and efficacy; regulatory restrictions that affect the sales of blockbuster drugs; and several other challenges in the international markets and the strategies adopted to deal with them. Investors will find the report particularly interesting since it analyzes the future potentials of major players and products in the field in a neutral manner.


This study surveys the market for small–molecules and biologic therapies for diseases caused by disorders of the immune system: therapies covered are either already used or will be used as medicine within the next 5 years. Promising drugs in the early stages of development are analyzed, but the emphasis is strongly upon drugs that are either on the market, or will be on the market within the time frame of this study.

In addition to profiling drugs and explaining the mechanism by which these drugs achieve their efficacy, the report breaks out the major medical markets for immune disease. This report does not cover drugs in pre–clinical testing in detail – even though some of the drugs with novel approaches are mentioned in the appropriate sections of the report. The report does not cover drugs that act to enhance the activity of the immune system against diseases such as cancer or opportunistic infections. Even though mechanisms of certain drugs help in the treatment of various cancer indications as well as immune diseases and are indicated for both, sales to those cancer–related indications are excluded as much as possible. Another therapeutic area that is excluded is Type–1 diabetes, though it is indeed an immune disease. This is excluded because most of the drugs are commonly used for both types of diabetes, and it is difficult to get an accurate idea about the sales exclusively for managing Type–1. Additionally, medical devices, or the direct costs of surgery to treat immune diseases, etc., are not covered. We believe that the market dynamics of these products and services are dramatically different than the pharmaceutical market and need to be dealt with as a separate report.

To know more about kindly visit :

Related reports

Global Protein Therapeutics Market Analysis 

Antiviral Therapeutics - Technologies, Markets and Companies 



Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter:!/BharatBook


Show HTML Embed Snippet

This release was submitted by a Newsbox user.
Any communication related to the content of this release should be sent to the release submitter.

Contact Info

From Name
From Email
From Company
Login to Submit Email

Author Info

Tag Cloud


More Releases


Add a Comment